[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100456741":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":47,"collaborators":49,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":20,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":20,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Guangzhou Burning Rock Dx Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants 40 years of age or older with cancer risk","EXPERIMENTAL","The study will aim to enroll participants 40 years of age or older with cancer risk. Specific cancer risks will be enriched to increase the number of cancer events that are observed during the study.",[13],"Device: OverC multi-cancer detection blood test",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","OverC multi-cancer detection blood test","Blood collection for the OverC multi-cancer detection blood test and standard-of-care screening with return of results",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Shangli Cai","CONTACT","13811823843","shangli.cai@brbiotech.com",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"West China Hospital, Sichuan University","RECRUITING","Chengdu","Sichuan","610044","China","CN",{"type":37,"coordinates":38},"Point",[39,40],104.06667,30.66667,{"lat":40,"lon":39},[43],{"name":44,"role":24,"phone":45,"phoneExt":20,"email":46},"Weimin Li","18980601009","weimin003@163.com",{"type":48,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[50],{"name":51,"class":52},"West China Hospital","OTHER","100456741","multi-cancer-early-detection-test-in-asymptomatic-individuals-prevent-100456741",false,"NCT05227534","Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)","A Prospective Multi-canceR Early-detection and interVENTional Study in Asymptomatic Individuals: PREVENT","PREVENT","Inclusion Criteria:\n\n* Participants must be able to provide a written informed consent form\n* Participants must not have received any colonoscopy, abdominal MRI\u002FCT, low-dose CT, or chest CT within 5 years before signing the informed consent form\n* Participants must be able to provide blood samples for study tests\n* Participants must be between 40 and 75 years old\n\nExclusion Criteria:\n\n* Individuals who have an acute infection or inflammation within 14 days prior to recruitment\n* Individuals with cancer-associated clinical symptoms or suspected of cancer\n* Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant\n* Recipient of blood transfusion within 7 days prior to recruitment\n* Individuals who have pure ground-glass opacity\n* Unable to provide blood samples for the multi-cancer early detection blood test\n* Individuals who are unable to tolerate standard-of-care cancer screening tests or have contraindications of standard-of-care cancer screening tests\n* Individuals who have taken medication with anti-tumor effects within 30 days prior to recruitment\n* Individuals who have received or are undergoing curative cancer treatment within three years prior to recruitment\n* Individuals with hemorrhagic diseases\n* Individuals with autoimmune diseases\n* Individuals who are pregnant or lactating\n* Individuals who have severe comorbidities that are not suitable for participating in the trial judged by researchers",true,"ALL","40 Years","75 Years",{"count":66,"type":67},12500,"ESTIMATED","INTERVENTIONAL",[70],"NA","PREVENT is a prospective, multicenter, interventional study evaluating the performance of the OverC multi-cancer detection blood test in asymptomatic individuals with cancer risk.",[73,74,75],"Cancer","Early Detection of Cancer","Circulating Cell-free DNA","2022-06-30",{"date":78,"type":79},"2022-07-06","ACTUAL",{"date":81,"type":79},"2022-06-01",{"date":83,"type":67},"2028-12-31",{"name":5,"class":6},1]